United Therapeutics (UTHR) Other Accumulated Expenses (2009 - 2026)

United Therapeutics has disclosed Other Accumulated Expenses across 18 years of filings, most recently posting $110.0 million for Q2 2026.

• In Q2 2026, Other Accumulated Expenses rose 15.67% year-over-year to $110.0 million; the TTM figure through Jun 2026 stood at $110.0 million (up 15.67% YoY), while the FY2025 annual figure was $72.6 million, down 22.44% from the prior year.
• Other Accumulated Expenses came in at $110.0 million for Q2 2026 at United Therapeutics, up from $100.8 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $154.5 million in Q1 2025 to a low of $32.5 million in Q4 2022.
• Average Other Accumulated Expenses over 5 years is $76.4 million, with a median of $75.2 million recorded in 2024.
• Year-over-year, Other Accumulated Expenses tumbled 36.51% in 2023 and surged 227.2% in 2024.
• Over 5 years, Other Accumulated Expenses stood at $32.5 million in 2022, then surged by 118.46% to $71.0 million in 2023, then surged by 31.83% to $93.6 million in 2024, then fell by 22.44% to $72.6 million in 2025, then jumped by 51.52% to $110.0 million in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $110.0 million in Q2 2026, $100.8 million in Q1 2026, and $72.6 million in Q4 2025.